Assessment of P Wave Peak Time and P Wave
Dispersion in Patients with COVID-19 Infection

elcik, deniz; Kelesoglu, Saban

doi:10.14744/etd.2021.06791

Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection

Şaban KELEŞOĞLU, (Erciyes Üniversitesi Tıp, Kardiyoloji Anabilim Dalı, Kayseri, Türkiye)

Deniz ELÇİK (Erciyes Üniversitesi Tıp, Kardiyoloji Anabilim Dalı, Kayseri, Türkiye)

Erciyes Medical Journal

3 2

Yıl: 2022 Cilt: 44 Sayı: 4 Sayfa Aralığı: 375 - 381 Metin Dili: İngilizce DOI: 10.14744/etd.2021.06791 İndeks Tarihi: 25-07-2022

Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection

Öz:

Objective: This study aims to evaluate P wave distribution (PD) and P wave peak time (PWPT) in COVID-19 patients. Materials and Methods: A total of 140 participants were recruited in our study. The COVID-19 group included 74 subjects, and the control group included 66 individuals. Between the two groups, PD was compared for electrocardiographic P-wave measurements, including abnormal P wave axis, P wave terminal force in V1 (PWTF), P wave max duration (Pmax), and PWPT. Results: It was determined that the Pmax and PD values of the patients infected with the COVID-19 virus were higher than the control group (p<0.001). PWPTD2 (p<0.001), PWPTV1 (p<0.001) and abnormal P wave axis ratio (p<0.05) were found to be significantly longer in COVID-19 patients. Serum CRP and WBC values were found to be significantly higher in COVID-19 patients (p<0.001, p<0.001, respectively). Also, a significant and positive correlation was detected between CRP and Pmax, PD, PWPTD2 and PWPTV1. There was the same correlation relationship between WBC with Pmax, PD, PWPTD2 and PWPTV1. Conclusion: Significant prolongation of PWPT and PD in COVID-19 patients may be predictive in determining the risk of developing atrial fibrillation.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020; 116(10): 1666–87.
2. Kelesoglu S, Yilmaz Y, Ozkan E, Calapkorur B, Gok M, Dursun ZB, et al. New onset atrial fibrilation and risk faktors in COVID-19. J Electrocardiol 2021; 65: 76–81.
3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130(23): 2071–104. Erratum in: Circulation 2014; 130(23): e270–1.
4. Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, et al. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol 2015; 66(25): 2899–906.
5. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27(2): 136–49.
6. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007; 50(21): 2021–8.
7. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020; 41(19): 1798–800.
8. De Flora S, Balansky R, La Maestra S. Rationale for the use of Nacetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J 2020; 34(10): 13185–93.
9. Çağdaş M, Karakoyun S, Rencüzoğulları İ, Karabağ Y, Yesin M, Gürsoy MO, et al. P wave peak time; a novel electrocardiographic parameter in the assessment of coronary no-reflow. J Electrocardiol 2017; 50(5): 584–90.
10. Yıldırım E, Günay N, Bayam E, Keskin M, Ozturkeri B, Selcuk M. Relationship between paroxysmal atrial fibrillation and a novel electrocardiographic parameter P wave peak time. J Electrocardiol 2019; 57: 81–6.
11. Tükek T, Akkaya V, Demirel S, Sözen AB, Kudat H, Atilgan D, et al. Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation. Am J Cardiol 2000; 85(7): 896–9, A10.
12. Kawano S, Hiraoka M, Sawanobori T. Electrocardiographic features of P waves from patients with transient atrial fibrillation. Jpn Heart J 1988; 29(1): 57–67.
13. Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998; 135(5 Pt 1): 733–8.
14. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985; 254(24): 3449–53.
15. Yilmaz R, Demirbag R. P-wave dispersion in patients with stable coronary artery disease and its relationship with severity of the disease. J Electrocardiol 2005: 38; 279–84.
16. Ozer N, Aytemir K, Atalar E, Sade E, Aksöyek S, Ovünç K, et al. P wave dispersion in hypertensive patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2000; 23(11 Pt 2): 1859–62.
17. Aytemir K, Ozer N, Atalar E, Sade E, Aksöyek S, Ovünç K, et al. P wave dispersion on 12-lead electrocardiography in patients with paroxysmalatrial fibrillation. Pacing Clin Electrophysiol 2000; 23(7): 1109–12.
18. Nishi K, Fujimoto S, Hisanaga S, Ogawa O, Kitamura K. Electrocardiographic assessment of incident atrial fibrillation in hemodialysis patients. Ther Apher Dial 2013; 17(1): 16–23.
19. Pieralli F, Biondo B, Vannucchi V, Falcone M, Antonielli E, De Marzi G, et al. Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. Eur J Intern Med 2019; 62: 24–8.
20. Soto-Gomez N, Anzueto A, Waterer GW, Restrepo MI, Mortensen EM. Pneumonia: an arrhythmogenic disease? Am J Med 2013; 126(1): 43–8.
21. Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. Respirology 2018; 23(3): 250–9.
22. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013; 381(9865): 496–505.
23. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol 2020; 72(7): 1059–63.
24. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008; 155(2): 303–9.
25. Amdur RL, Mukherjee M, Go A, Barrows IR, Ramezani A, Shoji J, et al; CRIC Study Investigators. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: Findings from the CRIC study. PLoS One 2016; 11(2): e0148189.
26. Ren M, Li X, Hao L, Zhong J. Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target? Ann Med 2015; 47(4): 316–24.

APA	Kelesoglu S, elcik d (2022). Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. , 375 - 381. 10.14744/etd.2021.06791
Chicago	Kelesoglu Saban,elcik deniz Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. (2022): 375 - 381. 10.14744/etd.2021.06791
MLA	Kelesoglu Saban,elcik deniz Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. , 2022, ss.375 - 381. 10.14744/etd.2021.06791
AMA	Kelesoglu S,elcik d Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. . 2022; 375 - 381. 10.14744/etd.2021.06791
Vancouver	Kelesoglu S,elcik d Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. . 2022; 375 - 381. 10.14744/etd.2021.06791
IEEE	Kelesoglu S,elcik d "Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection." , ss.375 - 381, 2022. 10.14744/etd.2021.06791
ISNAD	Kelesoglu, Saban - elcik, deniz. "Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection". (2022), 375-381. https://doi.org/10.14744/etd.2021.06791

APA	Kelesoglu S, elcik d (2022). Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. Erciyes Medical Journal, 44(4), 375 - 381. 10.14744/etd.2021.06791
Chicago	Kelesoglu Saban,elcik deniz Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. Erciyes Medical Journal 44, no.4 (2022): 375 - 381. 10.14744/etd.2021.06791
MLA	Kelesoglu Saban,elcik deniz Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. Erciyes Medical Journal, vol.44, no.4, 2022, ss.375 - 381. 10.14744/etd.2021.06791
AMA	Kelesoglu S,elcik d Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. Erciyes Medical Journal. 2022; 44(4): 375 - 381. 10.14744/etd.2021.06791
Vancouver	Kelesoglu S,elcik d Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection. Erciyes Medical Journal. 2022; 44(4): 375 - 381. 10.14744/etd.2021.06791
IEEE	Kelesoglu S,elcik d "Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection." Erciyes Medical Journal, 44, ss.375 - 381, 2022. 10.14744/etd.2021.06791
ISNAD	Kelesoglu, Saban - elcik, deniz. "Assessment of P Wave Peak Time and P Wave Dispersion in Patients with COVID-19 Infection". Erciyes Medical Journal 44/4 (2022), 375-381. https://doi.org/10.14744/etd.2021.06791